UK
Kevin Patterson
He/HimI am the US Access Solutions Lead at LCP Health. I am a veteran healthcare executive with nearly three decades of leadership in strategic consulting and industry innovation.
As a founding partner of Medical Marketing Economics, LLC (MME), I played a pivotal role as Administrative Partner and head of the Oncology Division, where I specialized in strategic positioning, indication prioritization, and optimizing market access.
Widely regarded as an expert in value-based decision-making, I now serve as co-lead for LCP’s US Access Solutions. In this capacity, I help shape the organization's national operations and service offerings, while partnering with both emerging biotech firms and established pharmaceutical leaders to guide commercial strategy, access planning, and launch readiness in a rapidly evolving healthcare environment.
My strategic insight and deep market experience continue to influence the way life sciences companies approach value, access, and innovation across the US healthcare system.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Is trade strategy part of your C-suite dialogue, and is it at a market or global level?
Natalie Rush explains why trade strategy must be a C-suite priority for pharma leaders, showing how aligning commercial, market access, and operational pathways can accelerate speed to market, control costs, and expand patient access globally.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
